Eyenovia announces updated strategy and corporate priorities to focus on shareholder value generation and immediate commercial opportunities

New york, april 08, 2024 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (micropine) and initiated a process to explore strategic alternatives to maximize shareholder value. as part of this process, the company plans to consider a wide range of options, including potential sale of assets of the company, a sale of the company, a merger, or other strategic action. in conjunction with the strategic process and focus on its late stage micropine asset, eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two fda-approved products.
EYEN Ratings Summary
EYEN Quant Ranking